Omega Healthcare Investors Inc.

▲ Bull Case

• ◆GGM anomaly represents clear structural mispricing: the market implies only 1.25% terminal dividend growth on a company whose AFFO is compounding at 3-8%/yr. A dividend raise — telegraphed for H2 2026/Q1 2027 — resolves the behavioral anchor suppressing the multiple, with GGM fair value jumping to $46/share at 2% terminal growth and $55/share at 3% terminal growth, representing 21-45% upside from current levels.
• ◆Operator health is at a 25-year high: EBITDARM coverage of 1.93x provides a 630bps buffer above the ~1.3x distress threshold. Even a 5% Medicaid cut compresses coverage only to ~1.75x — still healthy. LaVie resolved cleanly; Genesis paying full rent in Chapter 11. The #1 risk for a healthcare REIT is effectively well-contained.
• ◆UK care home platform at 10% acquisition yields generates 300-350bps accretive spread above WACC of 6.5-7.0%, among the widest in the global healthcare REIT sector. The April 2025 Scotland/Jersey deal (£259.8M at 10%) is replicable in a UK market with structural supply shortfall similar to U.S. SNFs, supporting sustained AFFO/share growth toward $3.62/share by FY2028E.

▼ Bear Case

• ◆Agemo loans represent a binary unresolved risk: two loan maturities (Dec 2024, Apr 2025) remain without public resolution. The operator has been restructured twice previously (2018, 2023). A write-down exceeding $100M would be AFFO-neutral but a significant management credibility and sentiment headwind, potentially delaying the multiple re-rating.
• ◆Medicaid policy risk is elevated under the One Big Beautiful Bill Act. Any enacted cuts would pressure operator margins and compress EBITDARM coverage from 1.93x, potentially delaying the dividend raise timeline and reducing AFFO growth momentum, particularly given the FY2026 deceleration guidance (+3-5% vs. FY2025's +8%).
• ◆The dividend raise is telegraphed but unconfirmed. A smaller-than-expected raise ($0.01-0.02/quarter) would disappoint income investors who have waited 9 years, and a 10th consecutive year of freeze by end-2027 would signal management lacks confidence in AFFO sustainability and could cause the stock to re-rate to a permanent discount.

“The central debate is whether OHI's 9-year dividend freeze reflects prudent capital discipline that preserved the company through multiple distress cycles (bull view) or signals management's fundamental lack of confidence in AFFO sustainability that justifies a permanent discount multiple (bear view). Bulls argue the freeze ends imminently given 87% payout ratio, 1.93x operator coverage, and deleveraged balance sheet, triggering a GGM-driven re-rating from 12.3x to 13-14x P/AFFO. Bears argue Medicaid policy uncertainty, the unresolved Agemo situation, and AFFO deceleration in FY2026 mean the raise will be delayed again, and that the LTIP structure (100% TSR-based, no AFFO or leverage metrics) creates management incentive misalignment. A secondary debate concerns whether UK care home expansion at 10% yields is genuinely accretive at scale or whether concentration in a single foreign market creates incremental currency and regulatory risk not fully priced by consensus. The demographic tailwind (48% growth in 80+ population by 2030) is broadly acknowledged but the market appears to discount it given near-term policy and operator credit uncertainty.”

• ◆Dividend raise announcement (H2 2026/Q1 2027): First raise in ~10 years signals AFFO sustainability; at $0.71/quarter and 6.5% target yield → $43.7/share; at 5.5% yield → $51.6/share
• ◆Genesis Chapter 11 clean resolution (Q3 2026): DIP repayment expected; removes largest active operator credit risk; estimated +$1-2/share if clean
• ◆Agemo loan public resolution: Binary catalyst; clean resolution provides +$1-2/share sentiment relief
• ◆UK care home acquisitions (ongoing): Each £200M+ deal at 10% yield adds $0.02-0.04/share in forward AFFO
• ◆Medicaid legislative clarity (FY2026-2027): Formal enactment or rejection of One Big Beautiful Bill Medicaid provisions resolves primary policy overhang
• ◆Q2 2026 earnings (July 2026): AFFO trajectory vs. $3.22/share pace; EBITDARM coverage update; any guidance on dividend raise timeline

• ◆Medicaid cuts enacted under One Big Beautiful Bill Act compressing operator EBITDARM coverage below 1.75x and delaying or preventing dividend raise
• ◆Agemo write-down exceeding $100M damaging management credibility and triggering sentiment re-rating even if AFFO-neutral
• ◆Dividend freeze extending to a 10th consecutive year (through end-2027) signaling fundamental management lack of confidence in AFFO sustainability
• ◆AFFO/share declining below FY2025A $3.10 on a full-year basis, indicating operator credit deterioration has exceeded the 1.93x coverage buffer
• ◆CEO Taylor Pickett departure before dividend raise execution, removing 25-year institutional knowledge and relationship capital with 88-operator base
• ◆EBITDARM portfolio coverage falling below 1.50x for two consecutive quarters, historically preceding operator defaults and impairments
• ◆LTIP structure (100% TSR-based) incentivizing dilutive acquisitions that expand TSR via stock re-rating but dilute AFFO/share